Successful treatment with plasmapheresis, cyclophosphamide, and cyclosporin A in type B syndrome of insulin resistance - A case report

被引:33
作者
Eriksson, JW [1 ]
Bremell, T
Eliasson, B
Fowelin, J
Fredriksson, L
Yu, ZW
机构
[1] Univ Umea Hosp, Dept Med, S-90185 Umea, Sweden
[2] Sahlgrens Univ Hosp, Dept Rheumatol, S-41345 Goteborg, Sweden
[3] Sahlgrens Univ Hosp, Dept Internal Med, S-41345 Goteborg, Sweden
[4] Falkenberg Hosp, Dept Med, Falkenberg, Sweden
关键词
D O I
10.2337/diacare.21.8.1217
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
CASE HISTORY- A woman born in 1949 was diagnosed in 1990 with systemic lupus erythematosus. She was treated with prednisolone, and <1 year later she presented with marked hyperglycemia. Large doses of insulin were given four times per day. Even though the patient was thin (BMI 17.4 kg/m(2)), very little improvement was seen. INVESTIGATIONS AND TREATMENT- Serum insulin levels were high, and a euglycemic clamp investigation confirmed severe insulin resistance. The patient's serum contained insulin receptor antibodies inhibiting insulin binding, and thus the patient had a type B syndrome of insulin resistance. After diet and exercise, glycemic control stabilized and insulin treatment was withdrawn. However, in late 1993 she was in a catabolic and hyperglycemic state even though prednisolone doses were increased and azathioprin was added. In early 1994 she was treated with plasmapheresis and cyclophosphamide i.v. Subsequently, cyclosporin A was started as a maintenance therapy in addition to azathioprin. There was a rapid and sustained clinical improvement. Since late 1994 and onward, there is no sign of diabetes or glucose intolerance and there are no demonstrable insulin receptor antibodies in the patient's serum. DISCUSSION - Severe type B insulin resistance may respond favorably to treatment with plasmapheresis and cyclophosphamide followed by cyclosporin A in combination with azathioprin.
引用
收藏
页码:1217 / 1220
页数:4
相关论文
共 9 条
[1]  
DEFRONZO RA, 1979, AM J PHYSIOL, V237, P214
[2]  
Gorden Phillip, 1993, P123
[3]   SYNDROMES OF INSULIN RESISTANCE AND ACANTHOSIS NIGRICANS - INSULIN-RECEPTOR DISORDERS IN MAN [J].
KAHN, CR ;
FLIER, JS ;
BAR, RS ;
ARCHER, JA ;
GORDEN, P ;
MARTIN, MM ;
ROTH, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (14) :739-745
[4]  
LU CY, 1993, J AM SOC NEPHROL, V4, P1239
[5]  
Moller David E., 1993, P49
[6]   TREATMENT BY PLASMA EXCHANGE OF A PATIENT WITH AUTOANTIBODIES TO THE INSULIN RECEPTOR [J].
MUGGEO, M ;
FLIER, JS ;
ABRAMS, RA ;
HARRISON, LC ;
DEISSERROTH, AB ;
KAHN, CR .
NEW ENGLAND JOURNAL OF MEDICINE, 1979, 300 (09) :477-480
[7]   LUPUS NEPHRITIS AND OTHER AUTOIMMUNE FEATURES IN PATIENTS WITH DIABETES-MELLITUS DUE TO AUTOANTIBODY TO INSULIN-RECEPTORS [J].
TSOKOS, GC ;
GORDEN, P ;
ANTONOVYCH, T ;
WILSON, CB ;
BALOW, JE .
ANNALS OF INTERNAL MEDICINE, 1985, 102 (02) :176-181
[8]   Effects of peroxovanadate and vanadate on insulin binding, degradation and sensitivity in rat adipocytes [J].
Yu, ZW ;
Posner, BI ;
Smith, U ;
Eriksson, JW .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 1996, 1310 (01) :103-109
[9]   Peroxovanadate and insulin action in adipocytes from NIDDM patients. Evidence against a primary defect in tyrosine phosphorylation [J].
Yu, ZW ;
Jansson, PA ;
Posner, BI ;
Smith, U ;
Eriksson, JW .
DIABETOLOGIA, 1997, 40 (10) :1197-1203